Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
At AAN Annual Meeting 2026, efgartigimod alfa showed durable adolescent gMG responses, with 80% achieving minimal symptom expression by cycle two and consistent improvements across treatment cycles.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.